Financial Performance - The company's operating revenue for 2019 was CNY 689,199,686.20, a slight increase of 0.01% compared to CNY 689,136,877.33 in 2018[15]. - The net profit attributable to shareholders decreased by 20.44% to CNY 81,391,942.86 from CNY 102,304,940.61 in the previous year[15]. - The net profit after deducting non-recurring gains and losses was CNY 77,724,698.14, down 21.43% from CNY 98,929,988.08 in 2018[15]. - The net cash flow from operating activities significantly increased by 704.53% to CNY 115,487,475.35, compared to CNY 14,354,706.28 in 2018[15]. - The total assets at the end of 2019 reached CNY 2,346,880,670.27, reflecting a growth of 10.52% from CNY 2,123,484,105.58 in 2018[15]. - The net assets attributable to shareholders increased by 4.95% to CNY 1,705,079,473.82 from CNY 1,624,616,636.52 in the previous year[15]. - Basic earnings per share decreased by 21.05% to CNY 0.30 from CNY 0.38 in 2018[15]. - The weighted average return on equity was 4.89%, down from 6.46% in the previous year[15]. - In 2019, the company achieved total revenue of CNY 689.20 million, a year-on-year increase of 0.01%[62]. - The net profit attributable to shareholders was CNY 81.39 million, a decrease of 20.44% compared to the previous year[62]. - The total assets reached CNY 2.347 billion, reflecting a year-on-year growth of 10.52%[62]. - The pharmaceutical intelligent manufacturing segment generated revenue of CNY 521.34 million, down 0.54% year-on-year, with a gross margin of 33.15%[63]. - The rehabilitation medical equipment segment reported revenue of CNY 167.86 million, an increase of 1.76% year-on-year[67]. Business Expansion and Strategy - The company has expanded its business into the rehabilitation medical equipment sector, with nearly 40 products launched in various rehabilitation fields by the end of the reporting period[31]. - The company has established a chemical synthesis division and acquired Zhejiang Jin'an to enhance its automation control capabilities in the traditional Chinese medicine extraction field[28]. - The company has developed an intelligent manufacturing execution system (iMES) and successfully applied it in several national-level intelligent manufacturing projects[30]. - The company aims to enhance its market presence in the rehabilitation medical equipment sector, focusing on technological innovation and product leadership to maximize sales outcomes[32]. - The company has adopted an EPC (Engineering Procurement Construction) model to optimize project costs and timelines, enhancing resource allocation efficiency[26]. - The company has extended its service offerings to the formulation production sector, creating a comprehensive solution that includes intelligent logistics and packaging systems[29]. - The company has identified the biopharmaceutical sector as a key growth area, aiming to cultivate it as a new business development direction[28]. - The company plans to utilize IoT, cloud storage, and big data technologies to upgrade approximately 30,000 rehabilitation medical devices currently in use, enhancing their functionality and data management capabilities[40]. - The company is focusing on expanding its market share in the maternal and child rehabilitation sector following its acquisition of Guangzhou Shiru, establishing a four-tier integrated rehabilitation system[36]. - The company plans to focus on expanding its business in chemical synthesis, plant extraction, and formulation areas in 2020[134]. Research and Development - Research and development expenses reached ¥44,359,681.26, an increase of 28.45% compared to the previous year, reflecting a significant rise in R&D investment[87]. - The company's R&D investment accounted for 6.44% of total revenue, up from 5.41% in the previous year[89]. - The company will continue to increase R&D investment, particularly in information technology, to enhance product intelligence and meet customer needs through new product development[118]. Market Trends and Opportunities - The rehabilitation medical device market in China reached a scale of 45 billion RMB in 2018, projected to grow to 103.3 billion RMB by 2022[51]. - The C-end user market in China's healthcare sector is expected to become a blue ocean market, with the company focusing on developing smart wearable rehabilitation devices tailored for domestic needs[41]. - The company highlights the potential for growth in the rehabilitation medical device sector, with only 30% of disabled individuals receiving basic rehabilitation services[115]. - The company notes that the number of rehabilitation institutions in China is significantly lower than in the U.S., indicating substantial growth potential in the rehabilitation medical field[115]. Corporate Governance and Compliance - The company has fulfilled its commitments regarding related party transactions during the reporting period[135]. - The company has committed to not engaging in any business that competes with Chengyitong, ensuring no conflicts of interest[141]. - The company has not experienced significant changes in project feasibility, and the pharmaceutical and biological engineering automation control system project has been put into production despite a decrease in orders due to macroeconomic factors[106]. - The company has not undergone any significant litigation or arbitration matters during the reporting period[152]. - The company has not issued any external guarantees during the reporting period, with both approved and actual amounts being zero[168]. Shareholder Information - The company has a total of 272,008,896 shares as of the report period, with no cash dividends or capital reserve transfers planned for 2019[128]. - The company reported a net profit available for distribution to ordinary shareholders, but no cash dividend distribution plan was proposed for 2019[133]. - The company’s stock unlock events included 29,081,504 shares on April 12, 2019, and 7,175,617 shares on April 22, 2019[189]. - The total number of ordinary shareholders at the end of the reporting period was 12,588, a slight increase from 12,538 at the end of the previous month[194]. - The largest individual shareholder, Liang Xuexian, owns 6.78% of the shares, amounting to 18,455,040 shares, with 13,841,280 shares under lock-up conditions[194]. Future Outlook - The company anticipates that healthcare expenditure will reach 6.5%-7% of GDP by 2020, driving growth in the pharmaceutical manufacturing industry[113]. - In 2020, the company plans to deepen its focus on biopharmaceutical manufacturing and expand its market share in rehabilitation medical devices, aiming to establish a leading position in the industry[117]. - The company will strengthen compliance management to improve efficiency and reduce costs, enhancing risk control across departments and subsidiaries[119].

北京诚益通控制工程科技股份有限公司 2019 年第三季度报告全文 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁学贤、主管会计工作负责人乌吉斯古楞及会计机构负责人(会 计主管人员)冯双声明：保证季度报告中财务报表的真实、准确、完整。 2019 年 10 月 1 北京诚益通控制工程科技股份有限公司 北京诚益通控制工程科技股份有限公司 2019 年第三季度报告全文 2019 年第三季度报告 第一节 重要提示 2019-080 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 2 北京诚益通控制工程科技股份有限公司 2019 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,329,633,682.32 | 2,123,484,105.58 | | 9.71% | ...

Financial Performance - Total operating revenue for the reporting period was ¥333,433,364.54, an increase of 2.22% compared to ¥326,179,929.46 in the same period last year[16]. - Net profit attributable to shareholders was ¥44,273,854.01, a decrease of 8.23% from ¥48,241,793.71 in the previous year[16]. - Net profit after deducting non-recurring gains and losses was ¥42,625,532.06, down 10.44% from ¥47,595,655.32 year-on-year[16]. - Basic earnings per share decreased to ¥0.16, down 11.11% from ¥0.18 in the same period last year[16]. - Diluted earnings per share also fell to ¥0.16, a decrease of 11.11% compared to ¥0.18 in the previous year[16]. - The weighted average return on net assets was 2.69%, down from 3.10% in the previous year[16]. - The total profit amounted to CNY 48.63 million, representing a year-on-year decrease of 12.89%[24]. - Net profit attributable to shareholders was CNY 44.27 million, down 8.23% year-on-year[24]. - The biopharmaceutical intelligent manufacturing business generated revenue of CNY 260.60 million, up 2.48% year-on-year, but net profit fell by 22.28% to CNY 25.20 million[42]. - The rehabilitation medical device segment, "Longzhijie," reported revenue of CNY 72.86 million, a growth of 7.70%, with net profit increasing by 25.54% to CNY 20.22 million[47]. Cash Flow and Assets - Net cash flow from operating activities reached ¥19,280,428.99, a significant increase of 387.08% compared to a negative cash flow of ¥6,715,984.53 in the previous year[16]. - Total assets at the end of the reporting period were ¥2,263,880,642.79, reflecting a growth of 6.61% from ¥2,123,484,105.58 at the end of the previous year[16]. - The company’s total assets reached CNY 2.26 billion, reflecting a year-on-year growth of 6.61%[41]. - The company’s cash and cash equivalents decreased from 233,812,491.75 RMB at the end of 2018 to 162,361,173.70 RMB by June 30, 2019, a decline of approximately 30.5%[132]. - The total liabilities amounted to CNY 577,092,915.98, up from CNY 483,778,994.90, indicating a rise of approximately 19.36%[135]. Investments and Acquisitions - The company established a joint venture, Beijing Chengyitong Wanjielang Biotechnology Co., Ltd., holding 55% of the shares, to promote chlorine dioxide disinfection technology in the medical market[26]. - The company acquired 65% of Guangzhou Zhanghe Intelligent Technology Co., Ltd., enhancing its position in the rehabilitation medical device sector[30]. - The company has expanded its market presence by acquiring a 55% stake in Jin'an Pharmaceutical Machinery and establishing a subsidiary in the U.S. for industrial hemp CBD extraction[43]. - The company signed a strategic cooperation agreement with Germany's ERGO-FIT GmbH & Co.KG to enhance its rehabilitation medical product system[31]. Research and Development - The company emphasizes continuous R&D investment to provide high-quality products and services in the health sector[25]. - The company’s R&D investment increased by 35.95% to RMB 19,327,613.67, up from RMB 14,216,882.30, reflecting a commitment to enhancing product development[52]. - The company has developed a comprehensive research and design system in the biopharmaceutical intelligent manufacturing sector, focusing on high-tech value-added research outcomes[35]. - The company is focusing on integrating resources and extending the industrial chain in the biopharmaceutical sector, including automation in raw material and formulation production[43]. Market Strategy and Expansion - The company plans to expand into the North American market, establishing a wholly-owned subsidiary in the U.S. to tap into new profit growth points[28]. - The company plans to expand its marketing efforts into county-level medical institutions and community healthcare, responding to national policies[49]. - The company aims to deepen its market penetration and achieve performance growth through a "one body, two wings, dual-wheel drive" development strategy[39]. - The company is focused on expanding its technology and product offerings in the biotechnology and medical device sectors[109]. Financial Management and Governance - The company plans not to distribute cash dividends or issue bonus shares[5]. - The company has committed to fulfilling performance promises related to net profits for the years 2016 to 2018, ensuring compliance with its obligations[84]. - The half-year financial report has not been audited, indicating a lack of external validation for the reported figures[86]. - The financial report was approved by the board of directors on August 27, 2019, reflecting timely governance practices[171]. Risks and Challenges - The company faces risks in technology development and new product innovation due to high R&D costs and long cycles[77]. - Increased market competition is anticipated as downstream clients demand more comprehensive solutions, prompting the company to enhance its R&D capabilities[78]. - The company has established a risk control system for R&D projects to mitigate potential development failures and cost overruns[77]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 12,494[118]. - Beijing Liweit Investment Co., Ltd. holds 25.81% of shares, totaling 70,209,771 shares, with 47,813,976 shares pledged[118]. - The largest individual shareholder, Liang Xuexian, holds 6.78% of shares, totaling 18,455,040 shares[118]. - The first employee stock ownership plan acquired a total of 3,584,426 shares, representing approximately 1.98% of the company's total equity, with a transaction amount of RMB 80,137,012.08 and an average price of RMB 22.357 per share[90].

北京诚益通控制工程科技股份有限公司 2019 年第一季度报告全文 北京诚益通控制工程科技股份有限公司 2019 年第一季度报告 2019-045 2019 年 04 月 1 北京诚益通控制工程科技股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁学贤、主管会计工作负责人乌吉斯古楞及会计机构负责人(会 计主管人员)冯双声明：保证季度报告中财务报表的真实、准确、完整。 2 北京诚益通控制工程科技股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 147,980,491.02 | 109,038,688.88 | 35.71% | | 归属于上市公司股东的净 ...

Financial Performance - The company's operating revenue for 2018 was approximately ¥689.14 million, representing a 24.14% increase compared to ¥555.13 million in 2017[19]. - The net profit attributable to shareholders for 2018 was approximately ¥102.30 million, an increase of 14.18% from ¥89.60 million in 2017[19]. - The total profit reached 118.98 million yuan, reflecting a year-on-year growth of 15.52%[27]. - The basic earnings per share for 2018 were ¥0.38, an increase of 8.57% compared to ¥0.35 in 2017[19]. - The company achieved total operating revenue of 68,913.69 million yuan, a year-on-year increase of 24.14%[52]. - The net profit attributable to shareholders was 10,230.49 million yuan, up 14.18% year-on-year[52]. - The gross profit margin for rehabilitation medical equipment was 70.97%, an increase of 5.49% compared to the previous year[62]. Cash Flow and Assets - The net cash flow from operating activities improved significantly to approximately ¥14.35 million, a 166.28% increase from a negative cash flow of ¥21.66 million in 2017[19]. - The total assets at the end of 2018 were approximately ¥2.12 billion, an increase of 11.84% from ¥1.90 billion at the end of 2017[19]. - The net assets attributable to shareholders at the end of 2018 were approximately ¥1.62 billion, reflecting a 6.01% increase from ¥1.53 billion at the end of 2017[19]. - The company reported an investment income of CNY 3.57 million, contributing 3.00% to total profit[75]. - The company has temporarily used CNY 50 million of raised funds to supplement working capital, with a remaining balance of CNY 16.41 million as of December 31, 2018[82]. Research and Development - The company invested 37.3 million yuan in R&D in 2018, accounting for 5.41% of its total revenue, and employed 301 R&D personnel[41]. - The company focused on the development of the iMES platform for digital workshop integration during the reporting period[31]. - The company is focused on technological innovation and product development as core drivers for growth in the competitive medical and rehabilitation equipment sectors[40]. - The number of R&D personnel increased to 301, accounting for 22.56% of the workforce, reflecting the company's commitment to innovation[72]. Market Expansion and Acquisitions - The company launched a new "pulse air mixing equipment" to expand its business scope in the veterinary medicine and health food sectors[30]. - The company acquired a controlling stake in Zhejiang Jin'an Pharmaceutical Machinery Co., further expanding its business into the traditional Chinese medicine market[27]. - The company completed four acquisitions from 2017 to 2018, extending its industrial chain and enhancing market presence[42]. - The company plans to deepen its focus on the pharmaceutical and biological intelligent manufacturing sector and expand its market share in rehabilitation medical devices, aiming to create new growth engines[96]. Shareholder and Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares for the year[6]. - The company reported no cash dividends or stock bonuses for the year 2018, with retained earnings carried forward to the next year[108]. - The company did not propose a cash dividend distribution plan for the reporting period despite having positive distributable profits, citing the need for liquidity for future investments in biomedicine and intelligent manufacturing projects[113]. - The stock increase and cash dividends reflect the company's commitment to returning value to shareholders while balancing growth investments[112]. Risks and Challenges - The company has faced risks as outlined in the future development outlook section of the report[5]. - The company faces risks in technology R&D and new product development, including potential deviations in R&D direction and high costs, which could adversely affect financial status if not managed properly[100]. - The company anticipates intensified market competition as downstream clients demand more comprehensive solutions, prompting a need for enhanced brand and product development strategies[102]. Corporate Governance and Management - The company has established measures to ensure that any business opportunities that may compete with its operations are prioritized for acquisition by the company[120]. - The company has a structured approach to managing potential conflicts of interest among its shareholders and controlling parties[120]. - The company has maintained a consistent leadership team, with key management personnel serving for several years, ensuring continuity in operations[188]. - The total remuneration paid to directors, supervisors, and senior management in 2018 amounted to CNY 3.0395 million[190].

北京诚益通控制工程科技股份有限公司 2018 年第三季度报告全文 北京诚益通控制工程科技股份有限公司 2018 年第三季度报告 2018-070 2018 年 10 月 1 北京诚益通控制工程科技股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁学贤、主管会计工作负责人乌吉斯古楞及会计机构负责人(会 计主管人员)冯双声明：保证季度报告中财务报表的真实、准确、完整。 2 北京诚益通控制工程科技股份有限公司 2018 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 2,062,608,487.28 | 1,898,600,744.37 | | 8.64% | ...

Financial Performance - Total operating revenue for the first half of 2018 was CNY 326,179,929.46, representing a 33.25% increase compared to CNY 244,791,601.06 in the same period last year[17]. - Net profit attributable to shareholders was CNY 48,241,793.71, up 39.24% from CNY 34,645,296.38 year-on-year[17]. - Net profit after deducting non-recurring gains and losses reached CNY 47,595,655.32, reflecting a 43.84% increase from CNY 33,089,927.04 in the previous year[17]. - Basic earnings per share increased to CNY 0.18, a rise of 28.57% compared to CNY 0.14 in the same period last year[17]. - Total profit reached 55.83 million yuan, reflecting a year-on-year growth of 41.14%[24]. - The company reported a total profit of ¥55,828,295.97, which is a 41.1% increase from ¥39,555,688.12 in the same period last year[145]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,968,653,586.19, marking a 3.69% increase from CNY 1,898,600,744.37 at the end of the previous year[17]. - Total liabilities amounted to CNY 378,508,754.50, compared to CNY 364,624,924.19 at the start of the period, showing an increase of approximately 3.8%[138]. - Current assets totaled CNY 1,148,777,015.71, an increase from CNY 1,118,892,037.21, reflecting a rise of about 2.4%[136]. - Total liabilities decreased to ¥224,532,215.86 from ¥251,926,988.53, a reduction of 10.8% year-over-year[145]. Cash Flow - The net cash flow from operating activities was negative CNY 6,715,984.53, an improvement of 51.08% compared to negative CNY 13,727,268.28 in the previous year[17]. - Operating cash inflow for the current period was CNY 310,029,719.12, up from CNY 210,619,395.02 in the previous period, representing an increase of approximately 47%[153]. - Cash inflow from investment activities totaled CNY 201,491,054.04, significantly higher than CNY 53,706,581.38 in the previous period[154]. - The ending cash and cash equivalents balance was CNY 156,037,303.42, down from CNY 308,540,248.98 in the previous period[154]. Research and Development - The company emphasizes continuous innovation and has established a comprehensive technology R&D system to support its growth strategy[31]. - Research and development expenses rose by 54.87% to approximately ¥14.22 million, primarily due to the increased scope from acquisitions[50]. Market and Business Expansion - The company is focused on expanding its rehabilitation medical device business, with products recognized by experts and gaining CE certification for international markets[28]. - The company is actively expanding its marketing network and optimizing its sales team to improve market coverage[43]. - The company plans to continue expanding its market presence and invest in new product development to drive future growth[145]. Acquisitions and Patents - The company completed acquisitions of Zhejiang Jin'an Pharmaceutical Machinery Co., Ltd. and Guangzhou Shiru Medical Technology Co., Ltd.[30]. - The company has accumulated 100 authorized utility model patents and 7 authorized invention patents in the field of pharmaceutical and biological information intelligent manufacturing[31]. - The rehabilitation medical device segment has obtained 48 authorized utility model patents and 9 authorized invention patents[32]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 8,494[119]. - The company has approved a total guarantee amount of RMB 17,000,000 for its subsidiaries, with an actual guarantee amount of RMB 4,078,500 during the reporting period, representing 2.50% of the company's net assets[98]. - The company distributed a cash dividend of RMB 0.56 per 10 shares to all shareholders[114]. Compliance and Governance - The company’s half-year financial report has not been audited[82]. - There were no significant litigation or arbitration matters during the reporting period[85]. - The company has not faced any penalties or rectification issues during the reporting period[86]. Financial Reporting and Accounting - The financial statements are prepared based on the actual transactions and events in accordance with the accounting standards issued by the Ministry of Finance[178]. - The company includes all subsidiaries in the consolidated financial statements, which consist of 12 entities[173]. - The company’s accounting policies ensure that the financial statements are true and complete[178].

Financial Performance - Total operating revenue for Q1 2018 was ¥109,038,688.88, an increase of 32.25% compared to ¥82,447,006.92 in the same period last year[8] - Net profit attributable to shareholders was ¥11,965,336.55, up 4.76% from ¥11,421,250.81 year-on-year[8] - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥11,972,277.43, representing a 9.85% increase from ¥10,898,428.40 in the previous year[8] - The company's operating revenue for Q1 2018 reached CNY 109.04 million, representing a 32.25% increase compared to the same period last year[21] - The net profit attributable to shareholders of the listed company was CNY 11.97 million, reflecting a 4.76% year-on-year growth[21] - The operating profit for the quarter was CNY 14,222,357.22, up from CNY 12,962,357.81 year-over-year, indicating a growth of approximately 9.71%[43] - The total profit for Q1 2018 was CNY 14,102,825.21, compared to CNY 13,486,757.81 in the previous year, marking an increase of around 4.57%[43] - The company reported a total comprehensive income for the period of CNY 11,801,571.70, compared to CNY 11,421,250.81 in the previous year, indicating an increase of about 3.32%[44] Cash Flow - The net cash flow from operating activities improved to -¥25,574,529.92, a 19.58% reduction in loss compared to -¥31,802,372.62 in the same period last year[8] - Cash received from sales of goods and services grew by 90.29% year-on-year, attributed to changes in the scope of consolidation and the maturity of receivables[20] - The cash flow from operating activities was CNY 144,267,002.14, a substantial increase from CNY 75,813,944.37 in the same period last year, representing an increase of about 90.00%[50] - Total cash inflow from operating activities was 149,568,027.82 CNY, compared to 76,880,975.31 CNY in the previous period, indicating a 94.4% increase[51] - Cash outflow from operating activities totaled 175,142,557.74 CNY, up from 108,683,347.93 CNY, representing a 61.1% increase[51] - The net cash flow from investing activities was -201,934.78 CNY, a significant decrease from 6,554,201.31 CNY in the previous period[52] - Cash inflow from investing activities was 127,257,808.23 CNY, compared to 29,007,321.39 CNY in the previous period, marking a 338.5% increase[52] - Cash outflow from investing activities was 127,459,743.01 CNY, up from 22,453,120.08 CNY, indicating a 467.5% increase[52] - The net cash flow from financing activities was -1,789,018.60 CNY, worsening from -292,275.34 CNY in the previous period[52] - The ending balance of cash and cash equivalents was 212,616,432.78 CNY, down from 240,398,475.51 CNY, reflecting a decrease of 11.6%[52] - The company reported a total cash outflow of 3,070,534.30 CNY in financing activities, compared to 326,295.14 CNY in the previous period, showing a significant increase[52] - The company’s cash and cash equivalents decreased by 27,782,042.73 CNY during the period, compared to a decrease of 25,540,446.65 CNY in the previous period[52] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,958,740,226.14, reflecting a 3.17% increase from ¥1,898,600,744.37 at the end of the previous year[8] - Total liabilities rose to CNY 412,359,906.81 compared to CNY 364,624,924.19 in the previous period[36] - The company's equity attributable to shareholders increased to CNY 1,544,432,027.24 from CNY 1,532,466,690.69[37] - Cash and cash equivalents decreased to CNY 176,370,354.43 from CNY 193,515,625.56[38] - Accounts receivable increased to CNY 276,374,584.34 from CNY 233,664,260.59[38] - Inventory rose to CNY 245,842,477.25 from CNY 231,295,277.14[38] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,269[14] - The largest shareholder, Beijing Liweit Investment Co., Ltd., holds 25.81% of the shares, with 34,560,000 shares pledged[14] Operational Strategy - The company plans to enhance its R&D capabilities and expand its product line to address increasing market competition and customer demands[10] - The company is establishing a risk control system for R&D projects to mitigate potential risks associated with new product development[11] - The company plans to continue expanding its business in line with its annual development strategy[21] - The company plans to expand its market presence and invest in new product development in the upcoming quarters[42] Procurement and Sales - The total procurement amount from the top five suppliers was CNY 23.77 million, down 11.29% compared to the same period last year[22] - The sales amount from the top five customers was CNY 44.13 million, a slight decrease of 0.49% year-on-year[22] - The proportion of procurement from the top five suppliers decreased to 32.66% from 48.16% year-on-year[22] - The proportion of sales from the top five customers decreased to 40.47% from 53.79% year-on-year[22] Expenses - Total operating costs amounted to CNY 96,840,183.21, up from CNY 69,575,746.31 in the prior period[42] - The company experienced a 263.79% increase in sales expenses compared to the same period last year, largely due to changes in the scope of consolidation[19] - The financial expenses decreased by 167.88% year-on-year, mainly due to increased interest income and changes in the scope of consolidation[19] - The financial expenses showed a net income of CNY -491,030.87, compared to CNY -183,301.84 in the previous year, indicating a worsening of financial costs[43] - The company reported a tax expense of CNY 2,301,253.51, compared to CNY 2,065,507.00 in Q1 2017, which is an increase of approximately 11.43%[43] R&D and Technology - The company reported that the automation control system project has not yet reached production and has not achieved expected benefits[26] - The company has no significant changes in its core technology team or key personnel during the reporting period[22]

Financial Performance - The company's operating revenue for 2017 was CNY 555,130,304.42, representing a 48.80% increase compared to CNY 373,059,156.35 in 2016[16] - The net profit attributable to shareholders for 2017 was CNY 89,601,428.10, a 66.74% increase from CNY 53,737,716.76 in 2016[16] - The net profit after deducting non-recurring gains and losses was CNY 83,942,413.61, up 63.45% from CNY 51,356,687.00 in 2016[16] - The total profit reached 102.99 million yuan, reflecting a year-on-year growth of 66.47%[24] - Net profit for the period was 89.60 million yuan, up 66.74% compared to the previous year[24] - The company achieved total revenue of CNY 55,513.03 million in 2017, representing a year-on-year growth of 48.80%[40] - Net profit for the year was CNY 8,960.14 million, an increase of 66.74% compared to the previous year[40] Assets and Liabilities - The total assets at the end of 2017 reached CNY 1,898,600,744.37, a 101.84% increase from CNY 940,653,398.18 at the end of 2016[16] - The net assets attributable to shareholders increased by 134.08% to CNY 1,532,466,690.69 from CNY 654,686,917.32 in 2016[16] - The total assets of the company reached CNY 189,860.07 million, marking a significant increase of 101.84%[40] - The company reported a net cash flow from financing activities of 280,298,514.58 yuan, a significant increase compared to the previous year[68] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 0.56 per 10 shares, with no bonus shares issued[4] - The cash dividend accounts for 100% of the total profit distribution amount[107] - The cash dividend for 2017 represents 11.33% of the net profit attributable to shareholders of the listed company[110] - The cash dividend for 2016 was RMB 10,200,333.60, which accounted for 18.98% of the net profit attributable to shareholders[110] Acquisitions and Business Expansion - The acquisition of Guangzhou Longzhijie Technology Co., Ltd. and Beijing Borihong Technology Development Co., Ltd. strengthened the company's main business[24][26] - The acquisition of Guangzhou Longzhijie contributed CNY 12,716.99 million in revenue and CNY 3,896.53 million in net profit, becoming a key driver for the company's growth[44] - The company successfully acquired Beijing Borihong, which generated CNY 4,881.11 million in revenue and CNY 1,044.00 million in net profit in 2017[43] - The company plans to acquire 100% equity of Guangzhou Longzhijie Technology Co., Ltd. through a combination of issuing shares and cash payment[112] Research and Development - The total revenue from research and development (R&D) reached 28,576,701.82 yuan, accounting for 5.15% of total operating income, a 76.46% increase year-on-year[66] - The company has obtained 74 utility model patents and 6 invention patents in its automation business segment[30] - The company emphasizes continuous innovation and development capabilities, focusing on product technology research and market expansion[41] - The company plans to enhance its R&D capabilities by improving collaboration and information sharing among departments, aiming to shorten the design and market introduction cycles of new technologies and products[92] Market Position and Strategy - The company is focused on expanding its market presence in rehabilitation medical devices and enhancing international cooperation[27] - The company aims to develop into a leading manufacturer of rehabilitation equipment and a comprehensive service provider for rehabilitation solutions[27] - The company has established a strong brand presence in the rehabilitation medical device sector, with over 200 partners and more than 20 branches domestically and internationally[33] - The company recognizes the risk of intensified market competition and plans to leverage its brand and financing advantages to adapt to market changes[95] Human Resources and Management - The company has implemented a comprehensive human resources management system to enhance employee skills and promote career development[35] - The total remuneration for directors, supervisors, and senior management in 2017 amounted to CNY 2.6074 million[191] - The company employed a total of 1,164 staff, with 358 in the parent company and 806 in major subsidiaries[193] - The company has a total of 33 financial personnel among its employees[193] Compliance and Governance - The company has ensured that minority shareholders had sufficient opportunities to express their opinions and that their legal rights were protected[104] - The company has committed to not engaging in any business that directly competes with its current operations[111] - The company has undertaken to ensure that no related party transactions will harm the interests of the listed company and its non-related shareholders[111] - The company has confirmed that all commitments made regarding the management of related party transactions have been fulfilled[117] Financial Management and Investments - The company engaged in cash asset management, with a total of 3,400 million CNY in entrusted financial management, all of which remained unexpired[142] - The company has not engaged in any entrusted loan activities during the reporting period[144] - The company has committed to ongoing investments in automation control and marketing support services, with a total of ¥54.17 million raised for these projects[78] Future Outlook - The management expressed optimism about future performance, projecting continued revenue growth and market expansion[181] - The company plans to continue expanding its market presence and exploring new strategies following the restructuring[166] - The company is committed to enhancing its research and development capabilities to drive innovation and meet evolving market demands[181]

北京诚益通控制工程科技股份有限公司 2017 年第三季度报告全文 北京诚益通控制工程科技股份有限公司 2017 年第三季度报告 2017-091 2017 年 10 月 1 北京诚益通控制工程科技股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人梁学贤、主管会计工作负责人乌吉斯古楞及会计机构负责人(会 计主管人员)代红敏声明：保证季度报告中财务报表的真实、准确、完整。 2 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | | --- | --- | --- | --- | --- | --- | | 总资产（元） | 1,882,905,646.19 | | 940,653,398.18 | | 100.17% | | 归属于上市公司股东的净资产 | 1,48 ...